Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
90 participants
INTERVENTIONAL
2020-08-06
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To minimize selection bias, subjects will be randomized to one of two groups: 1) Copper IUD (TCu380A); or 2) Copper and silver IUD (TCu380Ag), in a proportion 1:1. The randomization sequence was generated using the website http://www.randomization.com. Information on which treatment each woman will be assigned will be kept in a sealed, opaque envelope identified with a number. The envelope will only be opened after the participant has signed the ICF. Once the allocation is made, it cannot be changed. Only the professional who inserts the device knows the type of IUD. Patients will not know which type of IUD they will use to minimize performance bias, i.e., they will be blinded to the nature of the inserted device. Blinding will not be revealed until the end of the study.
Patients will be evaluated 3, 6 and 12 months after IUD insertion. This follow-up will be carried out at the Family Planning Clinic of the Gynecology Division at HC-FMUSP. After informed consent, patients will be asked about their current age, occupation, scholarship, ethnicity/race, date of cancer diagnosis, age at menarche and first sexual intercourse, number of lifetime partners, sexual orientation, number of pregnancies, deliveries and abortions, duration of breastfeeding, age of first and last birth, date of last menstruation, lifetime use of hormonal and emergency contraception, condom use, pregnancy desire after cancer treatment, comorbidities, type of surgery (conservative or mastectomy), current use of SERMS (selective estrogen receptor modulators; tamoxifen or raloxifene), aromatase inhibitors and anticoagulants, smoking (quantity and duration), alcoholism (frequency and dose), physical activity (type, time and duration), family history of malignant neoplasms. Tumor staging (TNM) and the immunohistochemical panel will also be recorded. In addition, the menstrual bleeding pattern will be questioned (through the recall of the last three months), including the interval between cycles, number of days of menstruation and number of pads or tampons used and the occurrence of menstrual cramps and the use of analgesics during the menstrual period. At inclusion, weight (kg), height (cm), blood pressure (mmHg), waist circumference (cm) and hip (cm) will be measured. At the time of the gynecological examination, Pap smear and endocervical swab for Chlamydia trachomatis (PCR) will be collected. Blood samples will be collected for the following laboratory tests: blood count and serum levels of FSH, estradiol, iron, ferritin, transferrin, and total iron binding capacity. Dependent variables will be considered: continuation rates, satisfaction, quality of life, pregnancy, rates, and reasons for discontinuation, with an emphasis on abnormal uterine bleeding. The independent variable will be the IUD type. The control variables will be the aforementioned clinical and sociodemographic parameters.
After being included in the study, the IUD will be inserted by a trained professional, if there is assurance that the patient is not pregnant. Hysterometry (in centimeters) will be measured and recorded before insertion of the IUD. After insertion, the pain attributed to the procedure will be questioned, in a global way, through a visual analogue pain scale. For greater uniformity, all IUDs will be inserted on an outpatient basis, without local anesthesia and/or sedation.
After 30 to 90 days of insertion, patients will undergo a physical examination (visualization of the IUD thread) and transvaginal ultrasound to verify if the IUD is in situ.
Patients will be evaluated 3, 6 and 12 months after IUD insertion. The clinical performance of the IUDs will be evaluated, including pregnancy, infection, perforation, expulsion, continuity of use, reasons for discontinuation, satisfaction with the method, menstrual bleeding pattern (PABC) and laboratory tests (blood count and serum levels of FSH, estradiol, iron, ferritin, transferrin, and total iron binding capacity). The PABC (pictorial blood loss assessment chart) tool will be used to collect information about menstrual bleeding. Increased uterine bleeding will be defined as a PABC score greater than 100 and/or bleeding duration greater than 7 days and/or by the woman's subjective perception of increased menstrual flow.
To assess quality of life, the Medical Outcomes Study 36-Item Short-Form Healty Survey (SF-36) questionnaire will be used. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) will also be included.
The collected data will be systematized in confidential spreadsheets for statistical analysis supervised by a qualified statistician. Quantitative description of the data (mean, median, standard deviation and relative frequency) will be performed and the analyzes will be performed using appropriate tests for each type of variable: quantitative variables will be analyzed by t test (parametric) or Mann-Whitney (non-parametric), according to the normality of the distribution; and categorical variables will be analyzed by chi-square (χ²) or Fisher's exact test, according to the number of observed events. The normality of data distribution will be evaluated using the Kolmogorov-Smirnov and Shapiro-Wilk tests. The time for the occurrence of events will be described in Kaplan-Meier curves and possible differences will be analyzed using the log-rank test and using proportional hazards models (Cox regression) using clinical-demographic and laboratory variables. The results will be reported as Relative Risk (RR), Odds Ratio (OR) and Hazard Ratios (HR), with 95% confidence intervals (95%CI). Both intention-to-treat and per-protocol analysis will be performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Copper IUD (TCu380A)
Women receiving an intrauterine device (IUD) containing 380mm² of copper.
Copper IUD (TCu380A)
An intrauterine device containing 380mm² of copper.
Silver and copper IUD (TCu380Ag)
Women receiving an intrauterine device (IUD) containing 380mm² of copper with a silver core.
Silver and copper IUD (TCu380Ag)
An intrauterine device containing 380mm² of copper with a silver core.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Silver and copper IUD (TCu380Ag)
An intrauterine device containing 380mm² of copper with a silver core.
Copper IUD (TCu380A)
An intrauterine device containing 380mm² of copper.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one vaginal sexual intercourse in life
* Wish to use intrauterine contraception
Exclusion Criteria
* Postmenopausal women
* Hysterectomized and/or bilaterally ovariectomized women
* Abortion less than four weeks
* Childbirth less than six weeks
* Known endometrial cavity changes
* Severe anemia (hemoglobin \< 8 g/dL)
* Severe thrombocytopenia
* Acute purulent cervicitis
* Current endometritis
* Acute pelvic inflammatory disease
* Genital tuberculosis
* Genital bleeding of unknown cause
* Cervical or endometrial cancer
* Wilson's disease
* Cognitive or psychiatric disorder that makes adherence to the study protocol unfeasible
* Tubal ligation
* Women who do not agree to participate in the study
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Edson Santos Ferreira-Filho
UNKNOWN
Nilson Roberto de Melo
UNKNOWN
Isabel Cristina Esposito Sorpreso
UNKNOWN
José Maria Soares Júnior
UNKNOWN
José Roberto Filassi
UNKNOWN
Kátia Cândido Carvalho
UNKNOWN
Walter da Silva Pinheiro
UNKNOWN
University of Sao Paulo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edmund C Baracat, PhD
Role: PRINCIPAL_INVESTIGATOR
Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Edson S Ferreira-Filho, MD
Role: primary
José M Soares-Junior, MD, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
26272819.3.0000.0068
Identifier Type: -
Identifier Source: org_study_id